FDA approves Opus Genetics' RYZUMVI, first eye drop for presbyopia in adults
The approval covers phentolamine ophthalmic solution for age-related near-vision loss, a condition affecting roughly 90% of US adults over 45.
Quiver Quantitative · +12 outlets
EU regulator backs Eli Lilly's oral GLP-1 Foundayo for obesity and type 2 diabetes
A positive CHMP opinion moves Lilly's oral obesity pill toward EU authorization, intensifying competition in the oral GLP-1 market.
Pharmaceutical Executive · +14 outlets
FDA approves Roche's at-home injection for thyroid eye disease, a first
Enspryng (satralizumab) becomes the first thyroid eye disease therapy that patients can self-administer at home, dosed every four weeks during maintenance.
Stock Titan · +14 outlets
FDA approves Gilead's once-daily Bixlenvo HIV regimen for adults
A new once-daily HIV treatment expands Gilead's portfolio as the company looks to extend its dominance in the HIV market.
scanx.trade · +14 outlets
Billionaire Patrick Soon-Shiong's ImmunityBio wins wider FDA approval for bladder cancer drug
The clearance covers the first treatment for BCG-unresponsive bladder cancer, broadening the label for Soon-Shiong's immunotherapy.
Billionaires.Africa · +6 outlets
FDA approves Viatris and Opus presbyopia eye drops, adding competition in near-vision market
The approval targets adults who struggle to focus up close, part of a widening field of presbyopia treatments.
Stock Titan · +4 outlets
Korea's first homegrown obesity drug priced at half the cost of rivals
Hanmi's domestic GLP-1 launch undercuts Mounjaro on price, raising the prospect of a price war in the weight-loss market.
mkbn.mk.co.kr · +8 outlets
Lilly's amylin combo raises the bar for obesity drug developers
Positive data on Lilly's amylin-based combination raises the competitive stakes for the next generation of obesity therapies.
Drug Discovery News · +7 outlets
Zealand Pharma and Generate Biomedicines sign $1.2B AI-designed obesity drug deal
The partnership pairs Zealand's peptide expertise with Generate's AI drug discovery platform to develop new obesity treatments.
Voice of Healthcare · +7 outlets
RevMed's pancreatic cancer drug cuts death risk by 60% versus chemo in trial
The pancreatic cancer data was among a slew of CHMP endorsements in Europe, alongside Lilly's obesity pill.
Stock Titan · +8 outlets
Legend Biotech wins FDA clearance for in vivo CAR-T therapy trial
The IND clearance covers LB2501, an investigational CD19/CD20 in vivo CAR-T therapy that generates immune cells inside the body.
Yahoo Finance · +13 outlets
Democrats allege Trump's pharma holdings surged as drugmakers won Medicare negotiation carveouts
The claim centers on whether drugmakers benefited from Medicare price negotiation carveouts while the president held pharma positions.
Fierce Pharma · +2 outlets
Alcon wins FDA approval for BRYTLY redness-relief eye drops
The drops are cleared to reduce eye redness within a minute and maintain whiteness for up to 12 hours.
Mugglehead Investment Magazine · +5 outlets
Pfizer to halt development of closely watched weight-loss drug
The decision removes one candidate from the crowded obesity pipeline as Pfizer weighs its metabolic disease strategy.
BusinessWorld Online · +4 outlets
Trump drug pricing deal projected to save $64.3B over 10 years
The projection comes as part of a broader roundup of medical industry news, including a $522M genetic testing fraud scheme.
Medical Economics · +2 outlets
Anavex gains FDA IND approval for Fragile X syndrome trial
Anavex plans to study its investigational drug in about 60 adult men; Fragile X has no FDA-approved treatment.
GuruFocus · +5 outlets
FDA continues 'reset' with new plan for reviewing rare disease drugs
The plan is part of an ongoing overhaul of the agency's drug review processes, with implications for rare disease developers.
BioPharma Dive · +1 outlets
Mark Cuban's Cost Plus Drugs teams up with Humana on employer drug costs
The partnership aims to lower prescription costs for employers, part of ongoing efforts to disrupt traditional pharmacy pricing.
Medical Economics · +1 outlets